TransMedics Group, Inc. (TMDX) Stock Score, Valuation & Financial Research
TransMedics Group, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 70/100.
Quick answer for TMDX
TransMedics Group, Inc. currently has a Wall Street Score of 70/100. The stored market price is $88.09. Its financial score is 46/100. Its valuation score is 93/100. These figures are a research snapshot, not a buy or sell recommendation.
What TransMedics Group, Inc. does
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquar
TMDX financial snapshot
- Wall Street Score:
- 70/100
- Current price:
- $88.09
- Market capitalization:
- $3.04B
- Revenue:
- $635.9M
- Net income:
- $171.9M
- Free cash flow:
- $133.6M
- Cash:
- $461.7M
- Total debt:
- $863.4M
- EPS:
- 5.60
- P/E ratio:
- 15.7x
- Financial score:
- 46/100
- Valuation score:
- 93/100
- Revenue score:
- 45/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $133.6M, showing positive cash generation.
- The balance sheet shows $461.7M of cash versus $863.4M of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 93/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 46/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research TMDX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.